Views: 3
Scientists from the University of Kentucky (UK) are embarking on a pioneering study to explore the benefits of cannabis-based medicines for patients with late-stage dementia. The research aims to provide alternative treatment options for symptoms such as agitation, fear, and distress, which are common in the final stages of dementia and cause significant emotional strain for patients and caregivers.
“Until we find a cure for dementias, there will always be a stage where the focus shifts to comfort and quality of life,” said Greg Jicha, a neurologist and director of clinical trials at UK’s Sanders-Brown Center on Aging. “Unfortunately, our current methods — such as sedatives and antipsychotics — often come with significant side effects. We need options that allow patients to remain alert, engaged, and cared for at home or in skilled facilities.”
The study, named LiBBY (Life’s-end Benefits of cannaBidiol and tetrahYdrocannabinol), is inspired by the story of a dementia patient named Libby. Her family’s search for alternative treatments to sedatives and antipsychotics motivated researchers to examine the potential benefits of THC and CBD for end-of-life dementia care.
Eligibility criteria for the study include being 40 years or older, having a dementia diagnosis, experiencing agitation and distress, and qualifying for hospice care. Participants will be accompanied by a study partner and will attend appointments at various research sites across the U.S., with in-house visits available when necessary.
The 12-week double-blind study will administer a THC and CBD combination to half of the participants, while the other half will receive a placebo. After the initial study period, the placebo group will also be offered the cannabis-based treatment to ensure all participants benefit.
Researchers emphasize that LiBBY is the first study of its kind to specifically examine the impact of cannabis medicine on improving the quality of life for individuals in the final stages of dementia. The results could contribute valuable data to the development of tailored cannabis-based treatments for end-of-life dementia care.
Read the whole article here.
